ArticleFrontiers in bioinformatics2026
Discovering TEAD4 modulators for hepatocellular carcinoma: a GAN-enabled generative modelling framework.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery of novel peptidomimetics against HSP90-HOP interactions towards improved cancer therapeutics using machine learning strategies.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liver diseases continue to impose a major global health burden, and therapeutic progress is constrained by the limited availability of validated small-molecule modulators. TEAD4, a central Hippo-YAP effector, has emerged as a key regulator of hepatic regeneration, survival, and disease progression, yet remains pharmacologically underexplored due to the scarcity of experimentally confirmed inhibitors. Critically, the limited number of known active compounds restricts effective supervised learning, necessitating data augmentation strategies capable of expanding TEAD4 relevant chemical space. Methods: To address this, we developed an integrative computational framework in which a conditional generative adversarial network was trained on QikProp-derived molecular descriptors to generate chemically realistic synthetic samples and mitigate class imbalance. This GAN driven augmentation enabled construction of a robust activity prediction model. XGBoost was selected as the classifier due to its strong performance on structured descriptor datasets and its ability to capture complex nonlinear relationships with strong generalization. The augmented dataset was used to train the XGBoost classifier for activity prediction and screen DrugBank compounds, producing a focused set of high confidence candidates. Shortlisted hits were refined using structure-based evaluation, toxicity filtering, and anticancer sensitivity prediction. Results: Quantum chemical analysis identified DB00169 (cholecalciferol) as a potential TEAD4-binding candidate supported by combined structural, dynamic, and electronic analyses. Molecular dynamics simulations further supported the stability of the TEAD4-ligand complex, indicating compact structural behaviour and thermodynamically favourable conformational states. Discussion: Overall, this work demonstrates that coupling GAN based molecular augmentation with XGBoost classification and molecular simulations provides a scalable strategy for identifying biologically meaningful TEAD4 modulators, supporting TEAD4 targeted drug discovery across liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.